MOXY: An open label pilot study of oxytocin for methamphetamine withdrawal in women, presented by Dr Sarah Catchlove, Research Fellow, Turning Point & A/Prof Shalini Arunogiri, Clinical Director on 21st Aug 2024
Overview:
This study investigated the effectiveness of an investigational medication, oxytocin, in improving a range of addiction treatment outcomes, including sleep, during a one-week residential withdrawal admission (detox), as well as the early recovery period.
The study has a specific focus on women as the literature suggests that responses to oxytocin may be sex-specific. Women have also been identified as an under researched group experiencing significant methamphetamine-related burden with no sex-specific treatment approaches currently available.
They will present the findings and discuss the learnings from conducting this novel inpatient detox study.
Objectives:
-
Share the findings from a recently completed open-label pilot study for women experiencing methamphetamine withdrawal.
-
Offer the audience the opportunity to learn from the challenges and successes encountered during the study.
-
Review the clinical outcomes of the pilot study and their implications for treatment practices.
Watch the presentation
About the presenter
Dr Sarah Catchlove is an early career researcher with a background in psychopharmacology, sleep, cognitive neuroscience, psychophysiology and neuroimaging. Sarah is currently overseeing several clinical trials exploring novel pharmacological treatments for substance use disorders.
A/P Shalini Arunogiri is Clinical Director at Turning Point and the Hamilton Centre, and an Associate Professor and NMHRC Emerging Leader at Monash Addiction Research Centre. Shalini has over 60 peer reviewed papers, and over $20M of research funding as a chief investigator on studies for novel treatments for substance use disorder. Her work focuses on addiction and related mental health comorbidity.